BiotechTube

Modified Measles Virus + Modified Measles Virus Lumbar Puncture

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Medulloblastoma, Childhood, Recurrent

Conditions

Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent

Trial Timeline

Feb 22, 2017 → May 10, 2023

NCT ID
NCT02962167

About Modified Measles Virus + Modified Measles Virus Lumbar Puncture

Modified Measles Virus + Modified Measles Virus Lumbar Puncture is a phase 1 stage product being developed by Brain Biotech for Medulloblastoma, Childhood, Recurrent. The current trial status is completed. This product is registered under clinical trial identifier NCT02962167. Target conditions include Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent.

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02962167Phase 1Completed

Competing Products

9 competing products in Medulloblastoma, Childhood, Recurrent

See all competitors
ProductCompanyStageHype Score
LY2940680 + LY2940680Eli LillyPhase 1
21
LDE225 + TMZNovartisPhase 2
35
LDE225NovartisPhase 1/2
32
Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + VincristineBrain BiotechPhase 1
11
CX 4945Brain BiotechPhase 1/2
14
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 yearsBrain BiotechPhase 1
23
PEP-CMVBrain BiotechPhase 1
23
Apatinib Combined With Temozolomide and Etoposide CapsulesBrain BiotechPhase 2
32
Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emeticsBrain BiotechPhase 2
29